No Data
No Data
Buy demand next week for Maesawa Chemical Industry and others.
[Next week's buying demand (table)] Code; Stock; Stock price impact; Buying demand; Credit ratio; Closing price; Change from previous day <9046>; Kobe Electric Railway; 390%; 35900; 0.06; 2772; -3 <2796>; PharmaLize; 345%; 7600; 7.09; 635; -2 <3198>; SFP; 315%; 77900; 0.15; 2163; -5 <8118>; King; 254%; 6100; 62.03; 755; 0 <9428>; Crops; 20
Pharmarise Holdings To Go Ex-Dividend On May 29th, 2025 With 14 JPY Dividend Per Share
July 2nd (Japan Standard Time) - $Pharmarise Holdings(2796.JP)$ is trading ex-dividend on May 29th, 2025.Shareholders of record on May 31st, 2025 will receive 14 JPY dividend per share. The ex-dividen
Takashimaya revises upwards on February 25, operating profit of 55 billion yen (previously 50 billion yen).
Takashimaya <8233> announced the revision of its financial estimates for the fiscal year ending February 2025. Operating revenue has been revised upward from 497 billion yen to 511.4 billion yen, and operating profit has been revised upward from 50 billion yen to 55 billion yen, reflecting the strong performance of inbound sales at domestic department stores. In addition, for the first quarter of the fiscal year ending February 2025, operating revenue was 120.125 billion yen, a year-on-year increase of 13.8%, and operating profit was 17.295 billion yen, an increase of 56.7% from the previous year. [Positive rating] Intellix <8940> revision.
Pharmarise Holdings: Announcement of differences between financial estimates and actual results for the entire fiscal year of May Heisei 6
Pharmarise Holdings: FY May 2024 financial results announcement (Japan GAAP) (Consolidated)
Pharmarise FY Loss Y351.00M Vs Net Y333.00M
Pharmarise Holdings Corp. (2796.TO) Japan Year Ended May 31 GROUP 2024 2023 Revenue Y54.47 bln Y52.03 bln Operating Profit Y916.00 m
No Data